AbCellera Biologics Inc (NAS:ABCL)

Q2 2026 Abcellera Biologics Inc Earnings Call Transcript

Aug 5, 2026 / 09:00 PM GMT

Release Date Price: $5.92 (-2.79%)

Transcript 10-Q8-K

Key Points

Positve

AbCellera Biologics Inc (ABCL) completed enrollment for the phase 2 study of ABCL-635 in treating hot flashes well ahead of schedule, with a top-line data readout expected very soon.
The company has secured significant new business development deals, including T-cell engager collaborations with Vertex and Jazz Pharmaceuticals, adding over $110 million in upfront cash.
AbCellera Biologics Inc (ABCL) maintains a strong liquidity position with over $565 million in cash and equivalents, plus roughly $110 million in committed government funding, providing a runway of at least three years.
The phase 1 data for ABCL-635 showed robust and sustained target engagement with a clean safety profile, including no perceptible increase in liver enzymes, which could be a key differentiator from existing small molecule treatments.
The company's T-cell engager platform has matured over five years, now including diverse CD3 binders, co-stimulatory antibodies, and scalable workflows, positioning it as a key asset for strategic partnerships.
AbCellera Biologics Inc (ABCL) added two experienced independent directors to its board, bringing complementary expertise in oncology, women's health, immunology, and endocrinology.

Negative

AbCellera Biologics Inc (ABCL) reported a net loss of roughly $55 million for Q2 2026, a significant increase from the $35 million loss in the same quarter of 2025.
Total revenue for the quarter dropped to approximately $4 million, down from $17 million in the prior year quarter, reflecting a decline in partnership revenue.
The company missed its internal goal of moving another program into IND-enabling activities in the first half of 2026, indicating potential delays in pipeline advancement.
Research and development expenses increased by approximately $7 million year-over-year, reflecting higher investment in internal programs and putting pressure on the bottom line.
The upcoming phase 2 data for ABCL-635 carries key scientific risks, including the unresolved question of whether blocking NK3R in the pre-optic nucleus is necessary for efficacy, which could impact the drug's potential.
The company acknowledged a pronounced placebo response in similar trials, which could affect the perceived efficacy of ABCL-635 in the upcoming readout.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ABCL.OQ - AbCellera Biologics Inc.
Q2 2026 Abcellera Biologics Inc Earnings Call
Aug 05, 2026 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Accelerers Q2 2026 business update conference call.

My name is Jonathan and I will facilitate the audio portion of today's interactive broadcast.

After the prepared remarks, we will host a question-and-answer session.

If you would like to ask a question, please press 1 to raise your hand.

Withdraw your question, press star 1 again.

At this time, I'd like to turn the call over to Trent Steinart, that seller is Chief legal and compliance officer.

You may proceed.

Thank you, hello everyone.

Thank you for joining us.

Earning.

I'm Trent Steinart of Sellers Chief Legal and Compliance Officer, Dr.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.